TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35250582
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with honeysuckle before rash occurred (Arm A)
Study: 35250582
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment with honeysuckle when rash occurred (Arm B)
Study: 34292474
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment blood pressure target of 140–179 mm Hg
Study: 33952195
Drug: Group-sequential two-arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-sequential two-arm trials
Study: 38454079
Drug: Aripiprazole augmentation
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole augmentation
Study: 34370925
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy interventions for daily activities and quality of life
Study: 32947434
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2)
Study: 34431493
Drug: LLF580 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLF580 300 mg subcutaneously every 4 weeks for 3 doses
Study: 32584117
Drug: Waitlist (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist (before treatment)
Study: 34376233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of default strategy and accountable justification strategy within flowsheet documentation
Study: 33185167
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of Platelet Rich Plasma (PRP), 3 injections at monthly intervals.
Study: 33185167
Drug: Single intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection of steroid.
Study: 37674551
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Exposure Therapy (VRET)
Study: 33895322
Drug: GRAd-COV2 vaccine
Normalized name: GRAd-COV2
DrugBank: GRAd-COV2 (DB16428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRAd-COV2 vaccine
Study: 34943312
Drug: Low-dose, high-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, high-frequency simulation training
Study: 34943312
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least monthly training
Study: 32065984
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT), n = 17
Study: 34982820
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed oil (SSO) therapy
Study: 32271833
Drug: READY for
Approvals — FDA: no, EMA: no, PMDA: no
Description: READY for MS (resilience group training program based on Acceptance and Commitment Therapy)
Study: 34843141
Drug: Standardised milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised milk-based formulation (SMBF)
Study: 34843141
Drug: Standardised non-milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised non-milk based formulation (SNMBF)
Study: 34843141
Drug: Hospital-based formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based formulation (HBF)
Study: 36321244
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NAC + ALA
Study: 34404592
Drug: Maintaining serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining serum potassium at ≥3.6 mEq/L
Study: 37221146
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept
Study: 33506805
Drug: Biological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatment (ACS)
Study: 33506805
Drug: Biological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatment (PRP)
Study: 33506805
Drug: Physical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical treatment (CM)
Study: 34076382
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine using buccal infiltration
Study: 35476650
Drug: RSVpreF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF vaccine (120 or 240 μg, with or without aluminum hydroxide)
Study: 35476650
Drug: RSVpreF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF vaccine (with aluminum hydroxide)
Study: 35476650
Drug: RSVpreF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF vaccine (without aluminum hydroxide)
Study: 35662486
Drug: Hydromorphone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.2 mg bolus via PCA)
Study: 35662486
Drug: Morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2 mg bolus via PCA)
Study: 32919400
Drug: Active NeuroStar
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active NeuroStar TMS monotherapy (n=48)
Study: 34324042
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg TXA
Study: 34324042
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg normal saline (placebo)
Study: 32949787
Drug: SRP followed
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP followed by single subgingival application of 1.2 % simvastatin gel (SMV group)
Study: 35594542
Drug: Dual pathway
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual pathway inhibition (DPI) using rivaroxaban 2.5 mg twice daily plus aspirin
Study: 35447283
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy followed by pre-operative chemotherapy (EXP)
Study: 35447283
Drug: Chemoradiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy and optional post-operative chemotherapy (STD)
Study: 35447283
Drug: Chemoradiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy and optional post-operative chemotherapy (STD+)
Study: 35447283
Drug: Chemoradiotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoradiotherapy without post-operative chemotherapy (STD-)
Study: 34221478
Drug: Parental knowledge
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental knowledge regarding antibiotic use for URTIs
Study: 34221478
Drug: Parental practices
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental practices regarding antibiotic prescriptions
Study: 35172876
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water injections (6 injections of sterile water, 0.1-0.3 ml per injection)
Study: 34500174
Drug: 30 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 hours of auditory-based targeted cognitive training (TCT) + treatment-as-usual (TAU)
Study: 35020047
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) + episodic future thinking (EFT) + contingency management
Study: 39111953
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg twice daily
Study: 32306485
Drug: PE plus
Normalized name: Acetaminophen/Phenylephrine Hydrochloride 500 MG-5 MG Oral Tablet [ORANYL PE PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE plus sertraline
Study: 39305459
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy
Study: 32820619
Drug: Single-dose apararenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose apararenone (5-320 mg)
Study: 32820619
Drug: Single-dose apararenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose apararenone (160 or 640 mg)
Study: 32820619
Drug: Eplerenone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (200 mg)
Study: 32600078
Drug: CRP >100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP >100 mg/L
Study: 32600078
Drug: Lactate dehydrogenase
Normalized name: Lactate dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate dehydrogenase >300 U/L
Study: 32896753
Drug: Standard breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard breast cancer treatment
Study: 36404704
Drug: Antibiotic resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic resistance condition
Study: 34371907
Drug: 1 cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cup of espresso coffee plus two cocoa-based products containing coffee (PC) twice per day for 1 month
Study: 35771315
Drug: Dexmedetomidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine plus ropivacaine (25 mL of 0.3% ropivacaine + 1 μg/kg dexmedetomidine)
Study: 35771315
Drug: Ropivacaine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (25 mL of 0.3% ropivacaine)
Study: 33340432
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g eicosapentaenoic acid (EPA) plus 1 g docosahexaenoic acid (DHA)
Study: 32664057
Drug: Acetaminophen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1,000 mg/d)
Study: 32931029
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment L+RT
Study: 32931029
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment M+RT
Study: 36399712
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg leniolisib twice daily for 12 weeks
Study: 36727855
Drug: NOL-guided fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NOL-guided fentanyl administration
Study: 35831797
Drug: TXA retrograde
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA retrograde injection (TXA-RI)
Study: 35831797
Drug: TXA-soaked absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA-soaked absorbable Gelfoam (TXA-Gel)
Study: 33739127
Drug: 3-month aspirin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month aspirin therapy with continued ticagrelor
Study: 33739127
Drug: 12-month aspirin
Normalized name: aspirin / menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month aspirin and ticagrelor
Study: 39222277
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg twice daily)
Study: 35441464
Drug: Opioid analgesic
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesic prescription at hospital discharge
Study: 35441464
Drug: Opioid analgesic
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesic use 4 weeks after ED presentation
Study: 34020962
Drug: Methylphenidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10 mg two times per day)
Study: 34020962
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules two times per day)
Study: 35661954
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no locoregional therapy)
Study: 32738479
Drug: 7.5-μg vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5-μg vaccine
Study: 32738479
Drug: 15-μg vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-μg vaccine
Study: 32738479
Drug: 30-μg vaccine
Normalized name: diphtheria toxoid vaccine, inactivated 30 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-μg vaccine
Study: 36412015
Drug: Yeahhh Baby!®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeahhh Baby!® ointment
Study: 33573421
Drug: Local pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local pain (Capsaicin gel applied)
Study: 33573421
Drug: Remote pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote pain (Capsaicin gel applied)
Study: 35271958
Drug: Concentric circle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentric circle method, 10 mL
Study: 35271958
Drug: Back-and-forth friction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Back-and-forth friction method, 3 mL
Study: 35271958
Drug: Back-and-forth friction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Back-and-forth friction method, 10 mL
Study: 32616489
Drug: Impryl (nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impryl (nutritional supplement)
Study: 35802374
Drug: Exercise-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-based physical therapy
Study: 32336038
Drug: Lenabasum (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenabasum (5 mg once daily, 20 mg once daily, or 20 mg twice daily for 4 weeks, followed by 20 mg twice daily for 8 weeks)
Study: 32729217
Drug: First-generation standard-of-care
Normalized name: First-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation standard-of-care basal insulin analogues (SOC‐BI; insulin glargine 100 U/mL or insulin detemir)
Study: 35096104
Drug: NXT15906F6 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXT15906F6 (250 mg/day)
Study: 35096104
Drug: NXT19185 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXT19185 (300 mg/day)
Study: 34221932
Drug: Fibrinogen intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen intra-articular injection
Study: 32103514
Drug: 8-mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg intravenous dexamethasone
Study: 35722590
Drug: Metacognitive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive Therapy (MCT)
Study: 34656207
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir (400 mg) plus rilpivirine (600 mg) every 4 weeks after a 4-week oral lead-in (direct-to-injection group)
Study: 34656207
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir (400 mg) plus rilpivirine (600 mg) every 4 weeks after a 4-week oral lead-in (oral lead-in group)
Study: 34656207
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care oral regimen (control group)
Study: 32460712
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose regimen of Mebendazole (100 mg twice a day for three consecutive days)
Study: 35793178
Drug: Pulsed Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Radiofrequency (PRF) plus Dexamethasone (5 mg in 1 mL)
Study: 35793178
Drug: Pulsed Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Radiofrequency (PRF) plus Normal Saline (1 mL)
Study: 34216862
Drug: Hydromorphone (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (32 mg total IV over 270 min)
Study: 35194646
Drug: Manual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual physical therapy
Study: 32627271
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg daily
Study: 35416190
Drug: HCA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCA group (calorie-restricted diet -700 kcal d-1 + HCA tablets)
Study: 34749822
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval training (HIIT) intervention, 12 weeks, bicycle-based, delivered twice weekly in a face-to-face, one-to-one setting.
Study: 34756178
Drug: IL-6 blockade
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 blockade (siltuximab 11 mg/kg or tocilizumab 8 mg/kg intravenously)
Study: 36387033
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light therapy (n = 13)
Study: 33617679
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg, twice daily)
Study: 36316861
Drug: Xuefu Zhuyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuefu Zhuyu Granules mimic (placebo) combined with Western medicine
Study: 33191263
Drug: Sarilumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab (200 mg and 400 mg) plus best available therapy (BAT)
Study: 32404035
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg or 150 mg twice daily
Study: 39185955
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg once daily
Study: 35379306
Drug: Standardized Brazilian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Brazilian green propolis extract (900 mg/day) for 10 days
Study: 34133205
Drug: Standard-dose gadoterate
Normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose gadoterate (0.1 mmol/kg)
Study: 35534374
Drug: Aficamten (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten (inhibitor for hypertrophic cardiomyopathy)
Study: 32591475
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg
Study: 34418858
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (age-matched healthy elderly, no stretching treatment)
Study: 32444619
Drug: Compassionate coach
Normalized name: coachwhip stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassionate coach (CC) image
Study: 34423693
Drug: Client-Centered (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-Centered (CC) intervention with telerehabilitation (TR) method
Study: 38060077
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy
Study: 37707817
Drug: High-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose trivalent influenza vaccine
Study: 35331539
Drug: Moderate‐carbohydrate diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate‐carbohydrate diet with calorie‐counting method (MCD‐CC)
Study: 33293185
Drug: Dexmedetomidine 10
Normalized name: dexmedeTOMIDine 1000 MG in 250 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 10 µg
Study: 34101892
Drug: Rivoceranib 201
Normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoceranib 201 mg with food
Study: 32510130
Drug: Kisspeptin-10 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kisspeptin-10 (4 µg/kg/h i.v.) without NK3Ra treatment
Study: 38360588
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents
Study: 34591356
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 mg bid (n=98)
Study: 32468672
Drug: sacubitril/valsartan 97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 97/103 mg bid
Study: 33033091
Drug: Patient-controlled regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled regional analgesia (PCRA) - ultrasound-guided subgluteal sciatic catheterisation, continuous infusion of 0.2% ropivacaine (15 mL loading dose, 8 mL/hour background, 6 mL patient-controlled bolus)
Study: 33033091
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) - morphine in boluses of 1 mg as needed, background infusion at 1 mg/hour
Study: 36364907
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Irvingia gabonensis (IG) extract
Study: 33462622
Drug: Bloodletting (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bloodletting (3 scheduled bloodlettings after a 3-month run-in period with 35 μg ethinylestradiol plus 2 mg cyproterone acetate)
Study: 33462622
Drug: Observation (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (after a 3-month run-in period with 35 μg ethinylestradiol plus 2 mg cyproterone acetate)
Study: 33990812
Drug: Vitrification solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrification solutions with sucrose (VS1)
Study: 33990812
Drug: Vitrification solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrification solutions without sucrose (VS2 and VS4)
Study: 33990812
Drug: Warming solution
Normalized name: CVS Flu & Sore Throat Warming Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming solution containing trehalose
Study: 33990812
Drug: Warming solution
Normalized name: CVS Flu & Sore Throat Warming Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming solution containing sucrose
Study: 34970487
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment
Study: 32787783
Drug: Prophylactic methoxamine
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic methoxamine infusion at 1 μg/kg/min (Group M1)
Study: 32787783
Drug: Prophylactic methoxamine
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic methoxamine infusion at 2 μg/kg/min (Group M2)
Study: 32787783
Drug: Prophylactic methoxamine
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic methoxamine infusion at 3 μg/kg/min (Group M3)
Study: 32787783
Drug: Prophylactic methoxamine
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic methoxamine infusion at 4 μg/kg/min (Group M4)